Galectin-3 Level in Ankylosing Spondylitis Patients

Status Completed

Clinical Trial Summary

Forty-five AS patients and 35 healthy controls were enrolled in this study. Patients diagnosed with AS according to Modified New York criteria were included in the study. Clinical and laboratory measurements, duration of symptoms, age and body mass index (BMI) of AS patients were performed and compared with age and BMI matched control group.

Clinical Trial Description

Detailed histories of all participants were obtained, and systemic and rheumatologic examinations were performed. We excluded all participants who had a history of hyperlipidemia, liver, renal, hematological, familial thyroid, neoplastic, autoimmune infectious diseases and receiving anti-inflammatory drugs. We measured serum galectin-3 levels using a commercial chemiluminescent microparticle immunoassay. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess disease activity in AS patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04746196
Study type	Observational
Source	Recep Tayyip Erdogan University Training and Research Hospital
Contact
Status	Completed
Phase
Start date	January 1, 2017
Completion date	August 30, 2017

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02685904` - A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis	Phase 3
Completed	`NCT02186873` - A Study of Golimumab in Participants With Active Ankylosing Spondylitis	Phase 3
Completed	`NCT01668004` - The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)	Phase 4
Completed	`NCT05051943` - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed	`NCT01934933` - Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis	Phase 4
Not yet recruiting	`NCT04875299` - Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
Completed	`NCT02758782` - NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis	Phase 4
Completed	`NCT02763111` - Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis	Phase 2
Active, not recruiting	`NCT02687620` - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Completed	`NCT02154425` - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers	Phase 1
Completed	`NCT01750528` - Prevalence and Progression of Periodontitis in Ankylosing Spondylitis	N/A
Completed	`NCT01463189` - Web-based Support to Manage Arthritis Pain	Phase 2
Completed	`NCT01091675` - Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs	Phase 3
Completed	`NCT00844805` - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)	Phase 3
Recruiting	`NCT00747578` - Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan	N/A
Completed	`NCT00715091` - Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis	Phase 4
Completed	`NCT01083693` - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs	N/A
Not yet recruiting	`NCT00517101` - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy	N/A
Completed	`NCT00367211` - Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.	Phase 3
Completed	`NCT00133315` - TNFalfa Blocking Treatment of Spondylarthropathies	Phase 4